Methods for testing andexanet potency
AssigneeAlexion Pharmaceuticals, Inc.
InventorsJoel Freeberg, Genmin Lu, Pamela Conley
Life of this patent
Estimating the term…
Abstract
The present disclosure relates kits and methods for measuring the potency of an andexanet sample in neutralizing a factor Xa inhibitor and restoring the activity of a wild-type factor Xa.
Claims17
A method for determining the activity of an andexanet sample, comprising:
- admixing a test sample comprising andexanet with a mixture comprising a human factor Xa (HFXa) and a direct factor Xa (fXa) inhibitor, wherein the molar ratio of the fXa to the fXa inhibitor is from 0.2:1 to 0.3:1;
- adding a chromogenic fXa substrate to the mixture, wherein the chromogenic fXa substrate is able to release a chromophore upon reaction with the HFXa;
- detecting the amount of released chromophore;
- and
- calculating, from the amount of the released chromophore, the activity of the andexanet sample in releasing the HFXa from the direct fXa inhibitor.
The method of any preceding claim, wherein the HFXa, after the test sample is added, has a concentration of about 8 to 14 nM.
The method of any preceding claim, wherein the direct fXa inhibitor is selected from the group consisting of betrixaban, apixaban, rivaroxaban, edoxaban, otamixaban, letaxaban and eribaxaban.
The method of any preceding claim, wherein the chromogenic fXa substrate is spectrozyme-Xa.
The method of any preceding claim, further comprising validating the activity of the andexanet sample with a standard curve generated with a reference andexanet sample.
A method for determining the activity of an andexanet sample, comprising:
- admixing a test sample comprising andexanet with a mixture comprising a bovine factor Xa (BFXa) and a direct factor Xa (fXa) inhibitor, wherein the molar ratio of the BFXa to the fXa inhibitor is from 0.15:1 to 0.25:1;
- adding a chromogenic fXa substrate to the mixture, wherein the chromogenic fXa substrate is able to release a chromophore upon reaction with the BFXa;
- detecting the amount of released chromophore;
- and
- calculating, from the amount of the released chromophore, the activity of the andexanet sample in releasing the BFXa from the direct fXa inhibitor.
Dependencies are inferred from the claim text.